Product Information
CARBAMAZEPINE 100 MG/5 ML SUSP is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.0925 per ML under NDC 70954024010. Its NADAC has been published 195 times since Jan 11, 2023.
FDA first approved this application on Oct 6, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/5mL
Manufacturer
ANI Pharmaceuticals, Inc.NDC
70954024010
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBAMAZEPINEApproval Type
Generic (ANDA)
FDA Application
ANDA214277FDA Approved
10/6/2022
TE Code
AB
On Market Since
10/6/2022
Pharmacological Classes
Price Statistics
The NADAC for CARBAMAZEPINE 100 MG/5 ML SUSP has been published 195 times since Jan 11, 2023, and over the history we have for it it has declined 17.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0925 per ML |
|---|---|
| All-time high | $0.1345 (Jan 10, 2024) |
| All-time low | $0.0925 (Sep 23, 2026) |
| 52-week high | $0.1134 |
| 52-week low | $0.0925 |
| Median price | $0.1111 |
| Average price | $0.1103 |
| Largest weekly change | +26.0% (May 17, 2023) |
| Weeks tracked | 195 |
| Tracking since | Jan 11, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbamazepine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBAMAZEPINE 100 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for CARBAMAZEPINE 100 MG/5 ML SUSP, manufactured by ANI Pharmaceuticals, Inc., is $0.0925 per ML (NDC 70954024010), effective Sep 30, 2026.
How has the price of CARBAMAZEPINE 100 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for CARBAMAZEPINE 100 MG/5 ML SUSP has declined 17.2%. It has been tracked across 195 weekly CMS publications since Jan 11, 2023.
What are the highest and lowest recorded NADAC prices for CARBAMAZEPINE 100 MG/5 ML SUSP?
Since Jan 11, 2023, the NADAC for CARBAMAZEPINE 100 MG/5 ML SUSP has ranged from a low of $0.0925 (Sep 23, 2026) to a high of $0.1345 (Jan 10, 2024), with a median of $0.1111 per ML.
Are there cheaper alternatives to CARBAMAZEPINE 100 MG/5 ML SUSP?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CARBAMAZEPINE 100 MG/5 ML SUSP in a comparable dosage form, but none are currently priced below it.
Who manufactures CARBAMAZEPINE 100 MG/5 ML SUSP?
CARBAMAZEPINE 100 MG/5 ML SUSP (NDC 70954024010) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.